vs
Side-by-side financial comparison of INVESTORS TITLE CO (ITIC) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $69.5M, roughly 1.3× INVESTORS TITLE CO). On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs -1.6%). INVESTORS TITLE CO produced more free cash flow last quarter ($25.4M vs $12.8M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 14.0%).
The Real Estate Title Insurance Company of Philadelphia was the world's first title insurance company.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
ITIC vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $69.5M | $92.9M |
| Net Profit | — | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | 13.8% | 24.1% |
| Net Margin | — | 25.0% |
| Revenue YoY | -1.6% | 23.3% |
| Net Profit YoY | — | 17.3% |
| EPS (diluted) | $3.97 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $69.5M | $92.9M | ||
| Q3 25 | $73.0M | $67.5M | ||
| Q2 25 | $73.6M | $63.2M | ||
| Q1 25 | $56.6M | $52.6M | ||
| Q4 24 | $70.6M | $75.4M | ||
| Q3 24 | $68.8M | $57.9M | ||
| Q2 24 | $65.4M | $52.7M | ||
| Q1 24 | $53.5M | $51.3M |
| Q4 25 | — | $23.2M | ||
| Q3 25 | $12.2M | $5.1M | ||
| Q2 25 | $12.3M | $-553.0K | ||
| Q1 25 | $3.2M | $-11.2M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | $9.3M | $-901.0K | ||
| Q2 24 | $8.9M | $-4.7M | ||
| Q1 24 | $4.5M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | 13.8% | 24.1% | ||
| Q3 25 | 20.7% | 5.1% | ||
| Q2 25 | 21.5% | -3.2% | ||
| Q1 25 | 7.2% | -24.3% | ||
| Q4 24 | 15.3% | 24.5% | ||
| Q3 24 | 16.8% | -4.3% | ||
| Q2 24 | 17.2% | -11.5% | ||
| Q1 24 | 10.8% | -10.7% |
| Q4 25 | — | 25.0% | ||
| Q3 25 | 16.7% | 7.5% | ||
| Q2 25 | 16.7% | -0.9% | ||
| Q1 25 | 5.6% | -21.4% | ||
| Q4 24 | — | 26.3% | ||
| Q3 24 | 13.5% | -1.6% | ||
| Q2 24 | 13.6% | -8.9% | ||
| Q1 24 | 8.5% | -7.5% |
| Q4 25 | $3.97 | $0.46 | ||
| Q3 25 | $6.45 | $0.10 | ||
| Q2 25 | $6.48 | $-0.01 | ||
| Q1 25 | $1.67 | $-0.23 | ||
| Q4 24 | $4.41 | $0.40 | ||
| Q3 24 | $4.92 | $-0.02 | ||
| Q2 24 | $4.70 | $-0.10 | ||
| Q1 24 | $2.40 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.6M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $268.3M | $354.6M |
| Total Assets | $363.1M | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.6M | $137.5M | ||
| Q3 25 | $110.8M | $135.4M | ||
| Q2 25 | $90.1M | $116.9M | ||
| Q1 25 | $81.7M | $112.9M | ||
| Q4 24 | $83.8M | $116.2M | ||
| Q3 24 | $112.9M | $101.7M | ||
| Q2 24 | $111.2M | $102.5M | ||
| Q1 24 | $135.0M | $110.6M |
| Q4 25 | $268.3M | $354.6M | ||
| Q3 25 | $278.0M | $321.9M | ||
| Q2 25 | $266.2M | $306.8M | ||
| Q1 25 | $254.4M | $295.5M | ||
| Q4 24 | $251.8M | $292.0M | ||
| Q3 24 | $271.3M | $257.5M | ||
| Q2 24 | $261.8M | $243.0M | ||
| Q1 24 | $254.0M | $233.9M |
| Q4 25 | $363.1M | $488.0M | ||
| Q3 25 | $363.3M | $453.3M | ||
| Q2 25 | $345.8M | $435.6M | ||
| Q1 25 | $333.8M | $424.6M | ||
| Q4 24 | $333.6M | $432.7M | ||
| Q3 24 | $352.0M | $390.4M | ||
| Q2 24 | $340.3M | $376.8M | ||
| Q1 24 | $329.5M | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.9M | $15.0M |
| Free Cash FlowOCF − Capex | $25.4M | $12.8M |
| FCF MarginFCF / Revenue | 36.5% | 13.8% |
| Capex IntensityCapex / Revenue | 8.0% | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $47.1M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.9M | $15.0M | ||
| Q3 25 | $17.2M | $22.1M | ||
| Q2 25 | $8.9M | $8.2M | ||
| Q1 25 | $-75.0K | $6.6M | ||
| Q4 24 | $29.8M | $22.2M | ||
| Q3 24 | $7.8M | $10.2M | ||
| Q2 24 | $8.4M | $18.5M | ||
| Q1 24 | $1.4M | $7.2M |
| Q4 25 | $25.4M | $12.8M | ||
| Q3 25 | $15.8M | $19.5M | ||
| Q2 25 | $7.3M | $81.0K | ||
| Q1 25 | $-1.4M | $-7.6M | ||
| Q4 24 | $22.4M | $8.5M | ||
| Q3 24 | $6.1M | $-9.2M | ||
| Q2 24 | $6.3M | $1.8M | ||
| Q1 24 | $-793.0K | $-6.8M |
| Q4 25 | 36.5% | 13.8% | ||
| Q3 25 | 21.7% | 28.8% | ||
| Q2 25 | 9.9% | 0.1% | ||
| Q1 25 | -2.5% | -14.5% | ||
| Q4 24 | 31.7% | 11.2% | ||
| Q3 24 | 8.8% | -15.9% | ||
| Q2 24 | 9.7% | 3.4% | ||
| Q1 24 | -1.5% | -13.3% |
| Q4 25 | 8.0% | 2.4% | ||
| Q3 25 | 1.8% | 3.9% | ||
| Q2 25 | 2.1% | 12.9% | ||
| Q1 25 | 2.4% | 27.0% | ||
| Q4 24 | 10.5% | 18.3% | ||
| Q3 24 | 2.5% | 33.5% | ||
| Q2 24 | 3.2% | 31.8% | ||
| Q1 24 | 4.2% | 27.3% |
| Q4 25 | — | 0.65× | ||
| Q3 25 | 1.40× | 4.35× | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | -0.02× | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | 0.84× | — | ||
| Q2 24 | 0.95× | — | ||
| Q1 24 | 0.32× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ITIC
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
